HER-2/ neu Expression in Osteosarcoma Increases Risk of Lung Metastasis and Can Be Associated With Gene Amplification
The DOI matches its Crossref record.
Abstract
The purpose of this study was to investigate whether Her-2/neu expression at diagnosis of osteosarcoma could provide biologic and prognostic information that predicts the risk of pulmonary metastases and outcome. Human epidermal growth factor (Her-2/neu) expression in 25 initial pretreatment osteosarcoma biopsies and 12 posttreatment pulmonary metastatic osteosarcoma resection specimens was assessed by standard immunohistochemical techniques on formalin-fixed paraffin-embedded tissue. As a screening analysis to determine if gene amplification may be a mechanism for increased Her-2/neu expression, FISH analysis was conducted on seven Her-2/neu immunostain-positive samples and five Her-2/neu immunostain-negative samples. Cytoplasmic Her-2/neu reactivity was identified in 11/25 (44%) of primary tumors and in 7/12 (58%) resection specimens from pulmonary metastases. Cytoplasmic Her-2/neu expression was associated with shorter overall metastasis-free survival. Her-2/neu gene amplification was identified by FISH analysis in six of the seven immunostain-positive samples but was also identified in two of the five immunostain-negative samples. Her-2/neu expression in patients with osteosarcoma is associated with an increased risk of metastasis and may define a subset of patients with a more aggressive tumor phenotype. Her-2/neu gene amplification may provide a mechanism for Her-2/neu overexpression in certain cases of osteosarcoma. Whether Her-2/neu expression influences outcome needs to be examined further in a prospective fashion. The hope is that Her-2/neu expression will identify patients who may benefit from the addition of directed biologic therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Lindsey, B. A., Markel, J. E., & Kleinerman, E. S. (2017) · Rheumatology and Therapy · doi:10.1007/s40744-016-0050-2 · Cited by 487
Chemotherapy resistance in osteosarcoma: current challenges and future directions
Chou, A. J., & Gorlick, R. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.7.1075 · Cited by 377
Osteosarcoma Development and Stem Cell Differentiation
Tang, N., Song, W.-X., Luo, J., Haydon, R. C., & He, T.-C. (2008) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-008-0335-z · Cited by 357
Osteosarcoma treatment: state of the art
Ta, H. T., Dass, C. R., Choong, P. F. M., & Dunstan, D. E. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-009-9186-7 · Cited by 314
Mialou, V., Philip, T., Kalifa, C., Perol, D., Gentet, J., Marec‐Berard, P., Pacquement, H., Chastagner, P., Defaschelles, A., & Hartmann, O. (2005) · Cancer · doi:10.1002/cncr.21263 · Cited by 286
Metadata
- Authors
- Zhou, H., Randall, R. L., Brothman, A. R., Maxwell, T., Coffin, C. M., & Goldsby, R. E.
- Venue
- Journal of Pediatric Hematology/Oncology
- Published
- 2003-01
- Volume
- 25
- Issue
- 1
- Pages
- 27-32
- ISSN
- 1077-4114 (ISSN-L)
- OpenAlex
- W2045471398
- Cited by
- 126
- References
- 0
- FWCI
- 8.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HER-2/ neu Expression in Osteosarcoma Increases Risk of Lung Metastasis and Can Be Associated With Gene Amplification. https://app.cochat.ai/papers/10.1097/00043426-200301000-00007
- The paper
- Zhou, H., Randall, R. L., Brothman, A. R., Maxwell, T., Coffin, C. M., & Goldsby, R. E. (2003). HER-2/ neu Expression in Osteosarcoma Increases Risk of Lung Metastasis and Can Be Associated With Gene Amplification. Journal of Pediatric Hematology/Oncology. https://doi.org/10.1097/00043426-200301000-00007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.